Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Eton Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $63.65, Eton Pharmaceuticals, Inc. trades at 35.7x trailing earnings, 12.9x sales and 20.8x book value, with an EV/EBITDA of 40.4. Over the last twelve months it generated about $143M of revenue and $51M of net income. It runs a gross margin of 69.2%, an operating margin of 28.8% and a net margin of 35.3%. It shows return on equity of 104.8%, return on invested capital of 35.4% and a free cash flow yield of 2.1%. On the balance sheet: a debt-to-equity ratio of 0.28 and a current ratio of 1.79. Over the past 52 weeks the share price ranged from $14.27 to $70.64, with a beta of 0.83.
Eton Pharmaceuticals, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Eton Pharmaceuticals, Inc. (ETON) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.46% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.51% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.46% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.51% / 33% · Receivables / Mkt Cap (36m) 1.67% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.46% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.51% / 33.33% · Receivables / Mkt Cap (24m) 1.67% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 15.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.7% / 33.33% · Receivables / Avg Assets (4Q) 16.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 14.7% / 33.33% · (Cash+ST Inv) / Total Assets 35.4% / 33.33% · (Cash+Recv) / Total Assets 52.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Eton Pharmaceuticals, Inc. (ETON) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Eton Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Eton Pharmaceuticals, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.